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Abstract
BACKGROUND & AIMS—Risks for some cancers increase with height. We investigated the
relationship between height and risk of esophageal adenocarcinoma (EAC) and its precursor,
Barrett’s esophagus (BE).
METHODS—We analyzed epidemiologic and genome-wide genomic data from individuals of
European ancestry in the Barrett’s and Esophageal Adenocarcinoma Consortium, from 999 cases
of EAC, 2061 cases of BE, and 2168 population controls. Multivariable logistic regression was
used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for associations between
height and risks of EAC and BE. We performed a Mendelian randomization analysis to estimate
an unconfounded effect of height on EAC and BE using a genetic risk score derived from 243
genetic variants associated with height as an instrumental variable.
RESULTS—Height was associated inversely with EAC (per 10-cm increase in height: OR, 0.70;
95% CI, 0.62–0.79 for men and OR, 0.57; 95% CI 0.40–0.80 for women) and BE (per 10-cm
increase in height: OR, 0.69; 95% CI, 0.62–0.77 for men and OR, 0.61; 95% CI, 0.48–0.77 for
women). The risk estimates were consistent across strata of age, education level, smoking,
gastroesophageal reflux symptoms, body mass index, and weight. Mendelian randomization
analysis yielded results quantitatively similar to those from the conventional epidemiologic
analysis.
CONCLUSIONS—Height is associated inversely with risks of EAC and BE. Results from the
Mendelian randomization study showed that the inverse association observed did not result from
confounding factors. Mechanistic studies of the effect of height on EAC and BE are warranted;
height could have utility in clinical risk stratification.
Keywords
Esophageal Cancer; Etiology; Risk Factors; Sex Differences
Esophageal adenocarcinoma (EAC) incidence increased 8-fold in the United States from
1973 to 2008.1 Incidence is up to 8-fold higher in males than in females2; however,
incidence rates for EAC continue to increase in both males and females.1 It is presumed that
almost all cases of EAC arise within a metaplastic epithelium of the esophagus known as
Barrett’s esophagus (BE). Gastroesophageal reflux (GER), obesity, and, to a lesser extent,
tobacco smoking are the primary risk factors for EAC and BE.3–7 On the other hand, CagA-
positive Helicobacter pylori colonization and regular use of aspirin and nonsteroidal anti-
inflammatory drugs are associated with reduced risks.8–11 A better understanding of risk
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factors for EAC may allow for both improved risk stratification and better insight into the
pathogenesis of this lethal condition.
Recently, attention has focused on the relationship between attained height and cancer. A
2011 meta-analysis of 11 prospective studies found that the risk of all cancers combined
increased by 10% and 15% per 10-cm increase in height in males and females,
respectively.12 Indeed, height may explain up to one half of the excess risks for all cancers
in males.13 Furthermore, height also is associated with increased risk of all-cancer
mortality.14 Although height is an independent risk factor and prognostic factor for cancers
of the colorectum, breast, endometrium, prostate, ovary, and melanoma, studies have
reported an inverse association between height and gastric cancer and with cancers of the
head and neck.14–16
The association between height and esophageal cancer is unclear. In the largest studies to
date, height was not associated with the risk of esophageal cancer in the Million Women
Study12 or with mortality from esophageal cancer in the Emerging Risk Factor
Collaboration study.14 However, the association with height may vary by histologic subtype
because EAC and esophageal squamous cell carcinoma (ESCC) have different risk profiles.
Height partly may explain the sex difference for EAC, although few studies have considered
EAC and ESCC separately in relation to height, and those that have done so were limited by
small numbers of cases. Height was associated inversely with risks of EAC and ESCC in
one study,17 whereas in another study height was associated inversely with EAC but not
with ESCC.18 In the National Institutes of Health AARP Diet and Health Study, there was
evidence of an inverse association between height and EAC, although this did not reach
statistical significance.19 In a prospective study in the general Norwegian population, a
statistically significant inverse association was observed between height and both EAC and
ESCC risks in males. In females, a similar relationship (albeit weaker and not statistically
significant) was seen for EAC but not ESCC.20 For BE, there was no association with height
in 2 previous studies.21,22 In this study, we aimed to clarify the association between height
and risks of EAC and BE.
We took advantage of epidemiologic and genome-wide genomic data available from a large
international consortium of BE and EAC studies—the Barrett’s and Esophageal
Adenocarcinoma Consortium (BEACON, http://beacon.tlvnet.net/). We undertook a pooled
analysis of original epidemiologic data from 14 population-based case-control and cohort
studies in BEACON to examine the association between height and risks of EAC and BE.
Because attained height varies by or is influenced by sex, smoking, socioeconomic status,
and various early life exposures, the risk estimates for the height-EAC and height-BE
associations obtained from conventional epidemiologic analyses may be confounded. We
therefore additionally performed a Mendelian randomization analysis using a genetic risk
score (GRS) (derived from 243 single-nucleotide polymorphisms [SNPs] associated with
height in European populations) (Wood AR et al, unpublished data, 2013) as an instrumental
variable (IV) for height to obtain unconfounded risk estimates for height-EAC and height-
BE associations.23–25 The IV method helps to overcome confounding because alleles are
allocated randomly from parents to offspring and are not associated with the wide range of
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risk factors that may confound the association with height.23,24,26 Further, the genetic
variants are measured reliably and are not affected by disease status or by study design.27
Methods
Study Population
Data concerning EAC and BE cases and controls were obtained from 14 epidemiologic
studies in BEACON. To avoid confounding from population stratification, we restricted our
analyses to individuals of European ancestry (confirmed in samples using principal
components analysis) that were included in the recent genome-wide association study
conducted by BEACON (Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility
Study).28 Histologic confirmation of EAC was performed for all EAC studies.6 Similarly,
BE was confirmed histologically via identification of goblet cells in metaplastic columnar
epithelium in a biopsy sample taken from the esophagus.7 A total of 1516 EAC cases, 2416
BE cases, and 2187 controls were available for pooling. We excluded participants with
missing information on weight or height (517 EAC cases, 355 BE cases, and 18 controls)
and those with extreme values (1 male control with height < 130 cm). Analyses thus were
based on 999 EAC cases, 2061 BE cases, and 2168 controls (Table 1). The study was
approved by the institutional review boards or research ethics committees of each
participating institution.
Statistical Analysis
The exposure and outcome data from the 14 studies were pooled and analyses of the single
data set were performed separately for EAC and BE and by sex. Self-reported current height
(at the time of interview) was the main exposure. Unconditional multivariable logistic
regression models were used to estimate odds ratios (ORs) and 95% confidence intervals
(CIs) for the association between height and risk of EAC/BE, adjusted for factors
significantly associated with EAC/BE in the BEACON data set. We examined the
association of height categorized into quartiles based on the distribution among controls
(males: <173, 173 to <178, 178 to <182, and ≥cm; females: <158, 158 to <163, 163 to <168,
and ≥168 cm), and also computed the OR for EAC and BE per 10-cm increase in height as a
continuous variable. To estimate the independent effect for height, we adjusted our analyses
by factors known to be associated with EAC and BE. Instead of adjusting for weight or body
mass index (BMI), which are associated with EAC and BE and appreciably correlated with
height, we used a weight-for-height variable (W/Hx) for such values of x that W/Hx was
highly correlated with weight (Pearson correlation coefficient, r, close to 1) but not
correlated with height (r close to 0).29 In our population, the optimal factor was x = 1.8 for
males (weight, r = 0.91; height, r = −0.005) and x = 1.5 for females (weight, r = 0.96;
height, r = −0.002). The fully adjusted models also included terms for age (categoric: <50,
50–59, 60–69, ≥70 y), education (<high school vs ≥high school), cigarette smoking status
(ever vs never), and reported GER symptom status (ever vs never). Participants with missing
data for covariables were included in the analyses using an additional category for missing
values. We examined potential nonlinearity of the association with height (continuous) with
penalized splines in generalized additive logistic models adjusted for the same covariables.
To assess possible effect modification, we performed stratified analyses by age, education,
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smoking status, GER symptoms, BMI, and weight. We included an interaction term in the
full model to assess the statistical significance of the differences in association across strata.
Finally, to evaluate potential differences in the associations across studies, we also obtained
summary risk estimates for height using a 2-stage approach among studies with data
available from both cases and controls: we first estimated study-specific ORs and associated
95% CIs, and then combined them using a random-effects meta-analytic model to calculate
a summary OR. Between-study heterogeneity was assessed using the I2 statistic.
Mendelian Randomization: Instrumental Variable Analysis
Genotyping of DNA from buffy coat or whole blood was performed using the Illumina
HumanOmni1-Quad platform (Illumina, San Diego, CA) as previously described.28 Call
rates were 95% or higher and all SNPs were in Hardy–Weinberg equilibrium over controls
given an a value of .0001. A recent genome-wide association study for height conducted by
the Genetic Investigation of ANthropometric Traits (GIANT) consortium identified 697
independent SNPs associated with height at genome-wide significance (P < 5 × 10−8)
(Wood AR et al, unpublished data, 2013). We used genotype information from 243 SNPs
common to the genotyping array used by both BEACON and GIANT to derive a weighted
GRS as an IV for height. For each SNP, participants received a score of 0, 1, or 2 for
carrying 0 (homozygous unassociated), 1 (heterozygous), or 2 (homozygous associated)
height-increasing risk alleles, and SNP GRS components were weighted by the per-allele
change in height (the increase in centimeters per 1 additional risk allele) reported for that
SNP in the genome-wide association study for height (Wood AR et al, unpublished data,
2013). Of 5228 participants, 4736 had complete genotype data on all 243 SNPs, 444 had
genotype data on 242 SNPs, and the remaining 48 had genotype data on at least 231 SNPs;
we imputed genotype data on those 492 participants with missing SNP data using mean
replacement.
The IV effect of height on risk of EAC/BE was estimated using the weighted GRS under an
additive model and the 2-stage control function IV method.30 By using controls only, we
first predicted height from the weighted GRS. In the second stage, we regressed case-control
status on the predicted values of height, the coefficient of which is the estimated effect of
height on EAC/BE. We used the F-statistic from the first-stage regression to assess the
strength of the instrument (F > 10 indicates sufficient strength to ensure the validity of the
IV method31). The estimates from the multivariable and IV analyses then were compared
using the Durbin form of the Durbin–Wu–Hausman statistic,32 in which rejection of the null
hypothesis indicates that the 2 risk estimates for height are not equal.
All analyses were performed using Stata 13.0 (Stata-Corp LP, College Station, TX).
Statistical tests were 2-sided and P values less than .05 were considered statistically
significant.
Results
Overall, 4134 males (1704 controls, 883 EAC cases, and 1547 BE cases) and 1094 females
(464 controls, 116 EAC cases, and 514 BE cases) from 14 studies were included in these
analyses. The numbers of cases and controls, and summary data for height by study are
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shown in Table 1. The mean height among male and female controls was 177.2 cm (SD, 6.9)
and 163.1 cm (SD, 6.4), respectively, whereas BE cases (males: 175.7 cm; SD, 7.3 cm;
females: 161.4 cm; SD, 6.5 cm) and EAC cases (males: 175.2 cm; SD, 7.2; females: 160.3
cm; SD, 7.7 cm) were shorter on average than controls. As expected, cases were
significantly more likely than controls to be obese, have ever smoked, and have had GER
symptoms (Table 2).
In the pooled analysis, we observed statistically significant inverse associations between
height and the risks of EAC and BE (Table 3). For males, the age-adjusted risks for EAC
and BE per 10-cm increase in height were as follows: 0.67 (95% CI, 0.60–0.76) and 0.71
(95% CI, 0.65–0.79), respectively. After adjusting for age, education, smoking status, W/Hx,
and GER symptoms, the OR was 0.70 (95% CI, 0.62–0.79) for EAC and 0.69 (95% CI,
0.62–0.77) for BE. Compared with males in the lowest quartile, males in the highest quartile
of height had a 52% (OR, 0.48; 95% CI, 0.38–0.62) lower risk of EAC and a 47% (OR,
0.53; 95% CI, 0.43–0.66) lower risk of BE. The results were unchanged when BMI was
included in the models instead of W/Hx (data not shown). In an analysis of a subset of
participants with waist-to-hip ratio data (n = 1123 participants from 5 studies), the
magnitude of the height-BE inverse association was the same when we adjusted for waist-to-
hip ratio instead of W/Hx (data not shown). Among females, the OR per 10-cm increase in
height was 0.57 (95% CI, 0.40–0.80) for EAC and 0.61 (95% CI, 0.48–0.77) for BE in the
fully adjusted model. The ORs did not differ significantly by sex (EAC: P interaction = .16;
BE: P interaction = .55), and the models suggested an inverse, linear, dose-response
relationship between height and both BE and EAC (ie, the restricted cubic spline models
[Figure 1] showed no consistent evidence of a nonlinear relationship; EAC: males, P
nonlinearity = .55; females, P nonlinearity = .02; BE: males, P nonlinearity = .23; females,
P nonlinearity = .59).
Similar results were found using random-effects models (Supplementary Figure 1) that
included only studies with both center-specific cases and controls (EAC risk per 10-cm
increase in height: males, fully adjusted summary OR, 0.73; 95% CI, 0.62–0.86; I2 = 0%;
females, fully adjusted summary OR, 0.76; 95% CI, 0.46–1.25; I2 = 0%; BE risk per 10-cm
increase in height: males, fully adjusted summary OR, 0.84; 95% CI, 0.72–1.00, I2 = 0%;
females, fully adjusted summary OR, 0.75; 95% CI, 0.53–1.05; I2 = 0%).
As expected, among both male and female controls, the mean heights were greater among
younger persons (<50 vs ≥50 y) and those with higher levels of education (<high school vs
≥high school). Nevertheless, the association of height with EAC and BE did not vary by age
(males: EAC P interaction = .69, BE P interaction = .38; females: EAC P interaction = .97,
BE P interaction = .13), or education level (males: EAC P interaction = .38, BE P
interaction = .08; females: EAC P interaction = .34, BE P interaction = .85). The inverse
associations between height and EAC and BE also were consistent across strata of smoking,
GER symptoms, BMI, and weight (Figure 2).
Instrumental Variable Analysis
Among males, the weighted GRS ranged from 6.04 to 8.11 (mean, 7.0; SD, 0.28) in
controls, the range was 5.92 to 7.95 (mean, 6.9; SD, 0.28) in EAC cases and 6.06 to 7.99
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(mean, 7.0; SD, 0.28) in BE cases. Among females, the weighted GRS ranged from 6.01 to
7.80 (mean, 7.0; SD, 0.29) in controls, 6.31 to 7.83 (mean, 7.0; SD, 0.30) in EAC cases and
6.10 to 7.75 (mean, 7.0; SD, 0.31) in BE cases. In controls and cases, the GRS was normally
distributed. Average height increased with increasing weighted GRS and was generally
higher in controls than in cases over the range of the GRS (Figure 3). As anticipated (based
on the principle of Mendelian randomization), the weighted GRS was not associated with
potential confounders including age (P = .57), sex (P = .69), education level (P = .77),
smoking status (P = .36), waist-to-hip ratio (P = .96), and GER symptoms (P = .47). The
weighted GRS was a strong predictor of height (males: F-statistic, 142.5; females: F-
statistic, 27.1). In the IV analyses, each 10-cm increase in height was associated with a 27%
lower risk of EAC (IV OR, 0.73; 95% CI, 0.46–1.15) and an 11% lower risk of BE (IV OR,
0.89; 95% CI, 0.60–1.31) in males, and a 37% lower risk of EAC (IV OR, 0.63; 95% CI,
0.15–2.63) and a 39% lower risk of BE (IV OR, 0.61; 95% CI, 0.27–1.39) in females;
although these did not reach statistical significance. The magnitude of the ORs in the IV
analyses were similar to those obtained from the epidemiologic analyses (Durbin–Wu–
Hausman test of difference between ORs from conventional methods and ORs from IV
methods: males, EAC, P = .82; BE, P = .18; females: EAC, P = .99; BE, P = .98).
Discussion
The results from this large pooled analysis of epidemiologic and genetic data from 14
studies show a consistent inverse association between height and risks of EAC and BE. The
ORs for EAC and BE per 10-cm increase in height were 0.70 (95% CI, 0.62–0.79) and 0.69
(95% CI, 0.62–0.77) for males, and 0.57 (95% CI, 0.40–0.80) and 0.61 (95% CI, 0.48–0.77)
for females, respectively. Although the point estimates in females were of stronger
magnitude, there were no statistically significant interactions between height, sex, and
disease risk. Adjustment for a range of potential confounders attenuated the risk estimates
somewhat, however, the inverse associations remained strong, statistically significant, and
consistent within all strata of examined potential effect modifiers. Furthermore, the
similarity in effects obtained from the conventional observational epidemiologic approach
compared with those obtained from the Mendelian randomization approach, using a
weighted GRS as an IV for height, suggests that the former was unlikely to be affected by
residual confounding.
Greater height is associated with increased risk of all cancers combined and with risk of
death from cancer. In the Million Women Study, total cancer risk increased by 16% per 10-
cm increase in height.12 A similar result was found in a cohort of about 90,000 female
Canadians (13% increase per 10-cm increase in height)33 and among males and females in
the Vitamins and Lifestyle Study (12% increase per 10-cm increase in height).13 In the
Emerging Risk Factor Collaboration study, risk of cancer-related death increased by 6% per
10-cm increase in height.14 However, not all cancers are associated with height and the
magnitude of the excess risk varies by cancer site (the greatest excess risk was seen for
melanoma).12,33 Height has been associated inversely with mortality from gastric cancer,14
and in a pooled analysis of 24 studies of head and neck cancers, an inverse association was
seen with height (10% and 15% reduced risk per 10-cm increase in height in males and
females, respectively).16 Height was not associated with esophageal cancer (all subtypes
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combined) in the Million Women Study or in the Emerging Risk Factor Collaboration study.
However, epidemiologic studies have shown that the major histologic subtypes of
esophageal cancer (EAC and ESCC) have different risk factor profiles. Our results are
consistent with those from previous studies examining the height association by esophageal
cancer subtypes,17–20 showing an inverse relationship between height and EAC. By contrast
to 2 previous studies,21,22 we found an inverse association between height and risk of BE.
Height itself is not considered a causal (or protective) factor for cancer, but rather a proxy
for exposures that affect cancer risk. An increased risk of cancer in taller individuals has
been suggested to be the result of higher cell turnover (mediated by steroid hormones or
growth factors) or a higher risk of malignant transformation among greater numbers of
cells.34 It is not intuitively obvious how height may reduce cancer risk. Instead, investigators
have proposed that inverse associations may be explained partly, if not entirely, by
confounding. For gastric cancer, H pylori colonization may confound the inverse association
with height because H pylori is associated with lower socioeconomic status (and thus shorter
attained height) and is related causally to gastric cancer. In a subset of BEACON controls
with data on H pylori colonization, we found that seropositive controls were shorter on
average than negative controls. However, H pylori colonization is associated inversely with
EAC and BE,10,11 and adjusting for H pylori status strengthened the inverse association with
height.
Childhood nutrition, illness, socioeconomic status, and other early life exposures are
important determinants of attained height.35 Although we adjusted for a wide range of
potential confounders, residual confounding may have occurred in our multivariable
analyses. We adjusted for known risk factors including past history of reflux and smoking
status. Because exposure data were pooled from numerous studies, we used dichotomized
variables. Although reducing the data in this way may have led to some residual
confounding, this is preferable to dropping observations or variables owing to incomplete
data. Nevertheless, risk estimates derived from Mendelian randomization methods are not
affected by confounding. Therefore, although the CIs from the IV analyses did include the
null, the similarity of the point estimates from both conventional and IV analyses provide
evidence that the inverse associations between height and risks of EAC and BE from
conventional analyses are unlikely to be caused by confounding.
We can only speculate as to how shorter stature is associated with increased risks of EAC
and BE. It is possible that shorter people have greater intra-abdominal pressure, promoting
development of a hiatal hernia and subsequent GER. We found tentative evidence to support
this hypothesis using the BEACON data set, in which we observed shorter average height
among controls with a hiatal hernia compared with controls without. Interestingly, however,
stratification of our cohort by the presence of GER symptoms did not show any significant
attenuation of the associations among those without GER symptoms, as might be expected if
promotion of GER were the sole mechanism by which height was related inversely to BE
and EAC. It also is tenable that shorter people may be more easily obese than taller people.
In any event, the inverse associations between height and disease risk remained in our
analyses, even after adjusting for body mass.
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Regardless of the mechanism, the association we report has potential clinical utility. The
prevention of EAC is hindered by a lack of predictors of both BE and EAC. The only risk
factor commonly used in clinical practice, the presence of GER symptoms, is neither
sensitive nor specific. The identification of further risk factors may allow construction of
more sophisticated and accurate risk stratification models, which may, in turn, be used to
decide who should undergo endoscopic screening for these conditions. Early attempts at
such models report modest performance characteristics, in part owing to the relatively weak
association of their predictor variables with the outcomes of interest.36–38
In summary, height was associated inversely with risks of EAC and BE, both in men and
women. These associations are unlikely to be explained entirely by confounding from
known risk factors, or through effect modification by any of a large number of risk factors.
Future investigations into why EAC and BE develop in only a subset of people who are
obese and/or have frequent GER symptoms should consider the role of height. Mechanistic
studies of the effect of height on the risks of BE and EAC are warranted, and this risk factor
may have utility in clinical risk stratification.
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Figure 1.
Restricted cubic spline models of the relationship between height and EAC and BE. (A)
EAC in males, (B) EAC in females, (C) BE in males, and (D) BE in females. Plots are
restricted to heights of 155 to 195 cm in males and 150 to 175 cm in females for clarity and
consistency.
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Figure 2.
The summary ORs and 95% CIs (per 10-cm increase) for associations between height and
risks of EAC and BE from stratified analyses. (A) EAC in males, (B) EAC in females, (C)
BE in males, and (D) BE in females.
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Figure 3.
Distribution of the weighted GRS among all subjects (left y-axis and histogram) and mean
height by GRS and case-control status (right y-axis and symbols) for (A) males and (B)
females.
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Table 3
ORs and 95% CIs for the Associations Between Height and EAC and BE
ORa (95% CI) ORb (95% CI)
EAC
  Males
    Quartile 1 1.00 (Ref) 1.00 (Ref)
    Quartile 2 0.55 (0.44–0.68) 0.55 (0.43–0.69)
    Quartile 3 0.59 (0.47–0.74) 0.61 (0.48–0.78)
    Quartile 4 0.46 (0.36–0.58) 0.48 (0.38–0.62)
    Per 10-cm increase 0.67 (0.60–0.76) 0.70 (0.62–0.79)
  Females
    Quartile 1 1.00 (Ref) 1.00 (Ref)
    Quartile 2 0.49 (0.29–0.83) 0.47 (0.27–0.82)
    Quartile 3 0.37 (0.21–0.66) 0.37 (0.20–0.68)
    Quartile 4 0.39 (0.20–0.75) 0.37 (0.18–0.75)
    Per 10-cm increase 0.59 (0.42–0.81) 0.57 (0.40–0.80)
BE
  Males
    Quartile 1 1.00 (Ref) 1.00 (Ref)
    Quartile 2 0.71 (0.59–0.86) 0.69 (0.57–0.84)
    Quartile 3 0.61 (0.50–0.74) 0.64 (0.52–0.80)
    Quartile 4 0.55 (0.45–0.67) 0.53 (0.43–0.66)
    Per 10-cm increase 0.71 (0.65–0.79) 0.69 (0.62–0.77)
  Females
    Quartile 1 1.00 (Ref) 1.00 (Ref)
    Quartile 2 0.89 (0.64–1.24) 0.82 (0.56–1.19)
    Quartile 3 0.58 (0.40–0.82) 0.57 (0.38–0.85)
    Quartile 4 0.50 (0.34–0.74) 0.50 (0.32–0.78)
    Per 10-cm increase 0.64 (0.52–0.78) 0.61 (0.48–0.77)
NOTE. Quartile definitions were as follows: males: <173 cm, 173 to <178 cm, 178 to <182 cm, and ≥182 cm; females: <158 cm, 158 to <163 cm,
163 to <168 cm, and ≥168 cm.
aAdjusted for age (categoric: <50, 50–59, 60–69, and ≥70 y).
bAdjusted for age (categoric: <50, 50–59, 60–69, and ≥70 y), education, cigarette smoking, weight/heightx, and GER; where x = 1.8 for males and
x = 1.5 for females.
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